BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38908982)

  • 1. Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery.
    Feng G; Han Y; Yang W; Shikora S; Mahawar K; Cheung TT; Targher G; Byrne CD; Hernandez-Gea V; Tilg H; Zheng MH
    Trends Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38908982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Esparham A; Shoar S; Mehri A; Khorgami Z; Modukuru VR
    Obes Surg; 2024 Jul; 34(7):2338-2346. PubMed ID: 38662250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024 Jun; ():1-70. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ; ;
    J Hepatol; 2024 Jun; ():. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis.
    Hofer BS; Simbrunner B; Hartl L; Jachs M; Balcar L; Paternostro R; Schwabl P; Semmler G; Scheiner B; Trauner M; Mandorfer M; Reiberger T
    Liver Int; 2023 Oct; 43(10):2220-2231. PubMed ID: 37469291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes.
    Castellano-Castillo D; Núñez-Sánchez MÁ; Balaguer-Román A; Martínez-Sánchez MA; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez CM; Frutos MD; Queipo-Ortuño MI; Cardona F; Ramos-Molina B
    Surg Obes Relat Dis; 2024 Jul; 20(7):652-659. PubMed ID: 38490825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis.
    Wang Q; Zhao H; Deng Y; Zheng H; Xiang H; Nan Y; Hu J; Meng Q; Xu X; Fang J; Xu J; Wang X; You H; Pan CQ; Xie W; Jia J
    J Hepatol; 2022 Dec; 77(6):1564-1572. PubMed ID: 36038017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Kumar J; Mohsin S; Hasan M; Bilal AR; Ali KM; Umer A; Hadi DZM; Nandlal S; Kumar S
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102261. PubMed ID: 38070828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
    Zeng J; Fan JG; Francque SM
    United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis.
    Hui VW; Wong GL; Wong VW; Chan HL; Lai JC; Tse YK; Lai MS; Yam TF; Li D; Fan X; Yip TC
    JHEP Rep; 2023 Sep; 5(9):100814. PubMed ID: 37546279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis.
    Hofer BS; Burghart L; Halilbasic E; Simbrunner B; Petrenko O; Mandorfer M; Stättermayer AF; Trauner M; Reiberger T
    Aliment Pharmacol Ther; 2024 Apr; 59(8):962-972. PubMed ID: 38409879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.